NAV
$100.97
AUM
$912.9M
Expense Ratio
-
Dividend Yield
0.00%
Beta
0.55
Currency
USD
| YTD | 1M | 3M | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|
| +19.01% | +8.92% | +16.95% | +53.23% | +21.50% | +11.80% |
| # | Symbol | Name | Weight |
|---|---|---|---|
| 1 | LLY | Eli Lilly and Co | 24.17% |
| 2 | JNJ | Johnson & Johnson | 20.28% |
| 3 | RPRX | Royalty Pharma PLC Class A | 5.22% |
| 4 | VTRS | Viatris Inc | 5.00% |
| 5 | MRK | Merck & Co Inc | 4.47% |
| 6 | PFE | Pfizer Inc | 4.19% |
| 7 | BMY | Bristol-Myers Squibb Co | 4.17% |
| 8 | JAZZ | Jazz Pharmaceuticals PLC | 3.84% |
| 9 | ELAN | Elanco Animal Health Inc | 3.16% |
| 10 | ZTS | Zoetis Inc Class A | 2.84% |
The underlying index includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines. The fund generally will invest at least 80% of its assets in the component securities of its underlying index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. The fund is non-diversified.
Inception Date: 2006-05-01